Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

View original at finance.yahoo.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Austedo annual revenues expected to be more than $2.5 billion by 2027

    80% confidence

  • Teva expects five additional biosimilar launches by 2027

    80% confidence

  • Teva raised its 2025 Austedo sales expectations following IRA pricing negotiations conclusion

    80% confidence

  • In 2025, Teva expects its generics business to be flat to up in low single digits in constant currency terms

    80% confidence

  • Teva is a Hold stock with Zacks Rank #3

    80% confidence

  • Teva expects an adjusted operating margin of 30% by 2027 through cost savings and continued growth of branded drugs

    80% confidence

  • Teva expects to launch Austedo in European markets in 2026

    80% confidence

  • Teva expects Uzedy total sales to be between $190 million and $200 million in 2025

    80% confidence

  • The outcome of the IRA pricing negotiations for Austedo went as expected

    80% confidence

  • Teva aims to double its global biosimilars sales by 2027

    80% confidence

  • CMS is expected to formally announce the agreement on a maximum fair price for Austedo in November 2025

    80% confidence

  • Austedo sales expected to exceed $3 billion by 2030

    80% confidence

  • Teva anticipates generating more than $5 billion in revenues from its branded products by 2030

    80% confidence

  • Teva expects to file a new drug application for olanzapine before the year ends

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play — Source | Via News | ViaNews EU